1. Home
  2. LOB vs URGN Comparison

LOB vs URGN Comparison

Compare LOB & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Live Oak Bancshares Inc.

LOB

Live Oak Bancshares Inc.

HOLD

Current Price

$39.48

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$43.74

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOB
URGN
Founded
2008
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
LOB
URGN
Price
$39.48
$43.74
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
$43.00
$29.29
AVG Volume (30 Days)
168.1K
796.8K
Earning Date
04-22-2026
05-06-2026
Dividend Yield
0.32%
N/A
EPS Growth
31.95
N/A
EPS
1.35
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$35.52
$129.09
Revenue Next Year
$16.03
$70.96
P/E Ratio
$29.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.36
$15.86
52 Week High
$44.53
$50.81

Technical Indicators

Market Signals
Indicator
LOB
URGN
Relative Strength Index (RSI) 38.99 47.51
Support Level $35.70 $42.00
Resistance Level $42.56 $43.93
Average True Range (ATR) 0.95 1.98
MACD -0.14 -0.60
Stochastic Oscillator 19.60 21.23

Price Performance

Historical Comparison
LOB
URGN

About LOB Live Oak Bancshares Inc.

Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: